Journal:

Article Title: A protocol for a lung neovascularization model in rodents

doi: 10.1038/nprot.2007.536

Figure Lengend Snippet: Drawing illustrating the inflation apparatus to distend lungs initially with a 3% paraformaldehyde/0.1% gluteraldehyde solution (shown in blue). Fixative is delivered to the tracheal catheter at 23 cm H2Opressure (determined by gravity) and to the vascular catheter at 100 cm H2O (determined by positive pressure from a peristaltic pump). Note: use a standard pressure monometer to predetermine the height of the mercury column needed for the pump to generate this pressure. The catheters connect first to a luer adapter, or a luer-adapted needle, and then, via a 4-way stopcock, to the tubing delivering fixative from each reservoir. Hemostat clamps (indicated by black bars) regulate the flow of fixative through the delivery tubes from each reservoir. A gate clip (heavy black bar) positioned on the tubing from the peristaltic pump is used to obtain/regulate pressure in the vascular reservoir.

Article Snippet: 0.28 mm) Luer adapter needles (Beckton-Dickinson for rat trachea and pulmonary artery—16 gauge stub adapter, cat. no. 427561; for mouse trachea, 22G, 0.7 mm × 25.4 mm, cat. no. 305155; and for pulmonary artery, 27G, 0.4 mm × 12.7 mm, cat. no. 305109) 3-way stopcock with male luer-lock adapter (Mallinckrodt, cat. no. 91040) Sterile specimen containers, 4 oz (Fisher Scientific, cat. no. 14-375-147) Single-edged industrial blades (Ted Pella, cat. no. 121-72) Cotton gauze sponges, 2 inch × 2 inch (Fisher Scientific, cat. no. 22-362-178) Kendall Tendersorb underpads, 17 inch × 24 inch (Owens & Minor, cat. no. 3583 007105) Single-use disposable scalpels, no. 15 blade (Fisher Scientific, cat. no. 08-927-5C) Shell vials, 15 mm o.d.

Techniques:

Journal: ESC Heart Failure

Article Title: Reduction in 90 day readmission rates utilizing ambulatory pulmonary pressure monitoring

doi: 10.1002/ehf2.14253

Figure Lengend Snippet: Mean event rates per patient per 180 days pre‐ and post‐PAP sensor implantation. HFH, heart failure hospitalization; IRR, incidence rate ratio.

Article Snippet: In the CHAMPION (CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in New York Heart Association Functional Class III Heart Failure Patients) trial, heart failure hospitalization (HFH) rates were lower in patients with ambulatory pulmonary artery pressure (PAP) monitoring guidance.

Techniques:

Journal: Vascular Pharmacology

Article Title: SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells

doi: 10.1016/j.vph.2020.106823

Figure Lengend Snippet: The SARS-CoV-2 spike protein S1 promotes the MEK phosphorylation in human cells. (A) Human pulmonary artery smooth cells ( N = 5) and (B) human pulmonary artery endothelial cells ( N = 3) were treated with recombinant full length S1 subunit of the SARS-CoV-2 spike protein (Val16 - Gln690) at 10 ng/ml for the durations indicated. Cell lysates were prepared and subjected to Western blotting using antibodies against phosphorylated MEK (p-MEK), MEK protein, phosphorylated Akt (p-Akt), and phosphorylated Stat3 (p-Stat3). Bar graphs represent means ± SEM. *Significantly different from 0 min at p < 0.05.

Article Snippet: Human pulmonary artery smooth muscle cells and human pulmonary artery endothelial cells were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA), and rat pulmonary artery smooth muscle cells were purchased from Cell Applications (San Diego, CA, USA).

Techniques: Phospho-proteomics, Recombinant, Western Blot

Journal: Vascular Pharmacology

Article Title: SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells

doi: 10.1016/j.vph.2020.106823

Figure Lengend Snippet: In rat cells, the SARS-CoV-2 spike protein S1 does not phosphorylate, but rather dephosphorylates MEK. Rat pulmonary artery smooth muscle cells were treated with recombinant full length S1 subunit of the SARS-CoV-2 spike protein (Val16 - Gln690) at 10 ng/ml for the durations indicated. Cell lysates were prepared and subjected to Western blotting using antibodies against phosphorylated MEK (p-MEK) and MEK protein. The bar graph represents means ± SEM ( N = 4). *Significantly different from 0 min at p < 0.05.

Article Snippet: Human pulmonary artery smooth muscle cells and human pulmonary artery endothelial cells were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA), and rat pulmonary artery smooth muscle cells were purchased from Cell Applications (San Diego, CA, USA).

Techniques: Recombinant, Western Blot

Journal: Vascular Pharmacology

Article Title: SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells

doi: 10.1016/j.vph.2020.106823

Figure Lengend Snippet: The SARS-CoV-2 spike protein S1 does not promote the phosphorylation of MEK in the presence of the neutralizing antibody against ACE2. Human pulmonary artery smooth muscle cells were pre-treated with the ACE2 antibody for 1 h and then treated with recombinant full length S1 subunit of the SARSCoV-2 spike protein (Val16 – Gln690) for 10 min. Cell lysates were prepared and subjected to Western blotting using antibodies against phosphorylated MEK (p-MEK) and MEK protein. The bar graph represents means ± SEM (N = 4).*Significantly different from untreated control at p < 0.05. NS denotes that the two values are not significantly different from each other at p < 0.05.

Article Snippet: Human pulmonary artery smooth muscle cells and human pulmonary artery endothelial cells were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA), and rat pulmonary artery smooth muscle cells were purchased from Cell Applications (San Diego, CA, USA).

Techniques: Phospho-proteomics, Recombinant, Western Blot, Control

Journal: Vascular Pharmacology

Article Title: SARS-CoV-2 spike protein-mediated cell signaling in lung vascular cells

doi: 10.1016/j.vph.2020.106823

Figure Lengend Snippet: The RBD only containing SARS-CoV-2 spike protein S1 does not activate the MEK phosphorylation. (A) Human pulmonary artery smooth muscle cells and (B) human pulmonary artery endothelial cells were treated with recombinant full length S1 subunit (Val16 - Gln690) or the RBD region of S1 subunit (Arg319 - Phe541) at 100 ng/ml for the durations indicated. Cell lysates were prepared and subjected to Western blotting using antibodies against phosphorylated MEK (p-MEK) and the MEK protein. Bar graphs represent means ± SEM ( N = 3). *Significantly different from 0 min control at p < 0.05.

Article Snippet: Human pulmonary artery smooth muscle cells and human pulmonary artery endothelial cells were purchased from ScienCell Research Laboratories (Carlsbad, CA, USA), and rat pulmonary artery smooth muscle cells were purchased from Cell Applications (San Diego, CA, USA).

Techniques: Phospho-proteomics, Recombinant, Western Blot, Control